Deferoxamine, the newly developed iron chelator LK-614 and N-α-acetyl-histidine in myocardial protection

• Verfasst von: Koch, Achim [VerfasserIn]
• Verfasst von: Loganathan, Sivakkanan [VerfasserIn]
• Verfasst von: Radovits, Tamas [VerfasserIn]
• Verfasst von: Sack, Falk-Udo [VerfasserIn]
• Verfasst von: Karck, Matthias [VerfasserIn]
• Verfasst von: Szabó, Gábor [VerfasserIn]
• Titel: Deferoxamine, the newly developed iron chelator LK-614 and N-α-acetyl-histidine in myocardial protection
• Verf.angabe: Achim Koch, Sivakkanan Loganathan, Tamas Radovits, Falk-Udo Sack, Matthias Karck, Gabor B. Szabó
• E-Jahr: 2010
• Jahr: 01 February 2010
• Umfang: 4 S.
• Fussnoten: Gesehen am 15.03.2023
• Titel Quelle: Enthalten in: Interactive cardiovascular and thoracic surgery
• Ort Quelle: Oxford : Oxford Univ. Press, 2002
• Jahr Quelle: 2010
• Band/Heft Quelle: 10(2010), 2 vom: Feb., Seite 181-184
• ISSN Quelle: 1569-9285
• DOI: doi:10.1510/icvts.2009.213280
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1839277742

Abstract

During cold storage of donor hearts, reactive oxygen species produced by intracellular redox-active chelatable iron potentially alter myocardial function. To reduce this cold-induced injury we investigated the efficacy of two new modifications of the well established histidine-tryptophan-ketogluterate (HTK) solution (Custodiol®) with the addition of N-α-acetyl-l-histidine and iron-chelators in a heterotopic rat heart transplantation model. The donor hearts were cardioplegically arrested with 20 ml cardioplegia and stored for 1 h. Then the hearts were anastomosed to the abdominal aorta and vena cava of the recipient (n=30). After 1 h reperfusion, myocardial function and energy charge potential were measured in three groups: HTK-1: addition of l-arginine and N-α-acetyl-l-histidine; HTK-2: addition of iron-chelators deferoxamine and LK-614; traditional HTK - control. After 1 h reperfusion, left ventricular systolic pressure (106±33 vs. 60±39, vs. 67±8 mmHg, P<0.05) and dP/dt minimal (-1388±627 vs. -660±446, vs. 871±188 mmHg/s, P<0.05) were significantly higher in the HTK-1 group. Energy charge potentials were not significantly different. This study showed that the novel modified HTK-1 solution improves myocardial contractility and relaxation after heart transplantation. Nevertheless, addition of the iron-chelators deferoxamine and LK-614 diminished these beneficial effects.